Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their Liposomal formulation in human colorectal cancer cell HCT116

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1321-1327

  Tippayamontri, Thititip ^a   Kotb, Rami ^b   Paquette, Benoit ^a   Sanche, Léon ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Cisplatin; Colorectal cancer; Lipoplatin and Lipoxal ; Liposome; Oxaliplatin

Indexed keywords

CISPLATIN; DNA; LIPOPLATIN; LIPOXAL; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPOSOME; PLATINUM COMPLEX;

ARTICLE; CELL STRAIN HCT116; CELL TRANSPORT; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG FORMULATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; ATOMIC ABSORPTION SPECTROMETRY; COLORECTAL TUMOR; COMPARATIVE STUDY; CYTOPLASM; DRUG SCREENING; METABOLISM; METHODOLOGY; PATHOLOGY; TIME;

ANTINEOPLASTIC AGENTS; CISPLATIN; COLORECTAL NEOPLASMS; CYTOPLASM; DNA; HCT116 CELLS; HUMANS; LIPOSOMES; ORGANOPLATINUM COMPOUNDS; SPECTROPHOTOMETRY, ATOMIC; TIME FACTORS; TUMOR STEM CELL ASSAY;

EID: 84856052774     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9494-3     Document Type: Article

References (23)

1. Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L (2004) Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22:3540-3548 (Pubitemid 41103660)
2. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F (2008) Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol 108:500-504
3. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23 (Pubitemid 46137553)
4. Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29:11-20 (Pubitemid 35191037)
5. Boulikas T (2004) Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12:3-12
6. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J (2006) Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 26:1489-1493
7. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T (2004) Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 24:2193-2200 (Pubitemid 39166294)
8. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG (2005) Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 13:589-595
9. Arienti C, Tesei A, Ravaioli A, Ratta M, Carloni S, Mangianti S, Ulivi P, Nicoletti S, Amadori D, Zoli W (2008) Activity of lipoplatin in tumor and in normal cells in vitro. Anticancer Drugs 19:983-990
10. Boulikas T (2007) Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin". Lipoplatin" as a chemotherapy and antiangiogenesis drug. Cancer Ther 5:349-376
11. Al-Sarraf MD (2007) The role of concurrent chemo-radiotherapy in patients with head and neck cancers: a review. Gulf J Oncolog 8-16
12. Patel A, Puthillath A, Yang G, Fakih MG (2008) Neoadjuvant chemoradiation for rectal cancer: is more better? Oncology (Williston Park) 22:814-826, discussion 826 (Pubitemid 352007347)
13. Paquette B, Little JB (1994) In vivo enhancement of genomic instability in minisatellite sequences of mouse C3H/10 T1/2 cells transformed in vitro by X-rays. Cancer Res 54:3173-3178
14. Scheeff ED, Briggs JM, Howell SB (1999) Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56:633-643 (Pubitemid 29406890)
15. Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T (2008) Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 62:577-584
16. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320 (Pubitemid 41130944)
17. Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL, Scheper RJ (1996) Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 74:1961-1967 (Pubitemid 27007142)
18. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ (2000) Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46:255-262
19. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD (1992) An intrastrand d (GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 89:10772-10776
20. Akiyama S, Chen ZS, Sumizawa T, Furukawa T (1999) Resistance to cisplatin. Anticancer Drug Des 14:143-151 (Pubitemid 29292311)
21. Desoize B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317-325 (Pubitemid 34615692)
22. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M (2005) Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 25:3031-3039
23. Zlatanova J, Yaneva J, Leuba SH (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 12:791-799 (Pubitemid 28294669)